PMID- 26484847
OWN - NLM
STAT- MEDLINE
DCOM- 20160906
LR  - 20151217
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 14
IP  - 12
DP  - 2015
TI  - Drug safety evaluation of lenvatinib for thyroid cancer.
PG  - 1935-43
LID - 10.1517/14740338.2015.1102883 [doi]
AB  - INTRODUCTION: Lenvatinib is an oral multitargeted tyrosine kinase inhibitor of 
      VEGFR1,2,3,4, FGFR1,2,3,4, PDGFR-alpha as well as RET and KIT signaling network. Its 
      activity against radioiodine-resistant differentiated thyroid cancer (DTC) has 
      been recently demonstrated. Patients, who were given lenvatinib, showed 
      significantly longer median progression free survival than placebo group, 18.3 vs 
      3.6 months, respectively. This review is focused on lenvatinib safety profile in 
      patients treated due to DTC and medullary thyroid carcinoma. Among the most 
      frequent lenvatinib-related adverse events (AEs) were hypertension, proteinuria, 
      diarrhea, appetite decrease, weight loss, nausea and stomatitis. Although a lot 
      of them were manageable, in 35-68% of patients dose reduction was required. 
      Nevertheless, only 15% of subjects withdrew the drug due to its toxicity. AREAS 
      COVERED: published results of clinical trials phase II and III investigating both 
      safety and efficacy of lenvatinib in thyroid cancer. EXPERT OPINION: Lenvatinib 
      shows acceptable safety profile in patients with thyroid carcinoma. 
      Treatment-related side effects are usually manageable by dose modifications or by 
      concomitant non-pharmacological and pharmacological treatment. However, the early 
      recognition of any potential drug toxicity is crucial to avoid serious 
      complications as well as to keep a patient on drug as long as the treatment is 
      beneficial.
FAU - Krajewska, Jolanta
AU  - Krajewska J
AD  - a Nuclear Medicine and Endocrine Oncology Department , M.Sklodowska-Curie 
      Memorial Cancer Center and Institute of Oncology , Gliwice Branch, Gliwice , 
      Poland.
FAU - Kukulska, Aleksandra
AU  - Kukulska A
AD  - a Nuclear Medicine and Endocrine Oncology Department , M.Sklodowska-Curie 
      Memorial Cancer Center and Institute of Oncology , Gliwice Branch, Gliwice , 
      Poland.
FAU - Jarzab, Barbara
AU  - Jarzab B
AD  - a Nuclear Medicine and Endocrine Oncology Department , M.Sklodowska-Curie 
      Memorial Cancer Center and Institute of Oncology , Gliwice Branch, Gliwice , 
      Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20151020
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinolines)
RN  - EE083865G2 (lenvatinib)
RN  - Thyroid cancer, medullary
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Carcinoma, Neuroendocrine/*drug therapy/pathology
MH  - Disease-Free Survival
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Phenylurea Compounds/administration & dosage/adverse effects/*therapeutic use
MH  - Protein Kinase Inhibitors/administration & dosage/adverse effects/therapeutic use
MH  - Quinolines/administration & dosage/adverse effects/*therapeutic use
MH  - Thyroid Neoplasms/*drug therapy/pathology
OTO - NOTNLM
OT  - E7080
OT  - differentiated thyroid cancer
OT  - lenvatinib
OT  - tyrosine kinase inhibitor
EDAT- 2015/10/21 06:00
MHDA- 2016/09/07 06:00
CRDT- 2015/10/21 06:00
PHST- 2015/10/21 06:00 [entrez]
PHST- 2015/10/21 06:00 [pubmed]
PHST- 2016/09/07 06:00 [medline]
AID - 10.1517/14740338.2015.1102883 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2015;14(12):1935-43. doi: 10.1517/14740338.2015.1102883. 
      Epub 2015 Oct 20.